Clinical Trials
34 trialsYL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Gilead Sciences
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
Sun Yat-sen University
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
PRECIOUS
Japan Breast Cancer Research Group
ALPHABET
Spanish Breast Cancer Research Group
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Qilu Pharmaceutical Co., Ltd.
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
Shanghai Yizhong Pharmaceutical Co., Ltd.
TROPiCS-02
Gilead Sciences
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
Sun Yat-sen University
A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
RemeGen Co., Ltd.
TULIP
Byondis B.V.
Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
ATTAIN
Nektar Therapeutics
ASCENT
Gilead Sciences
VICTORIANE
Centre Hospitalier Universitaire de Besancon
Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer
Zhejiang Cancer Hospital
SYSUCC-002
Sun Yat-sen University
NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy
Fudan University
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Boehringer Ingelheim
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Eisai Inc.
Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
BOLERO-3
Novartis
PERS
Sun Yat-sen University
CARIN
iOMEDICO AG
Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer
National Cancer Institute (NCI)
Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)
ChineseAMS
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer
Dana-Farber Cancer Institute
Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer
Hellenic Oncology Research Group
Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer
Danish Breast Cancer Cooperative Group